Virtual Library
Start Your Search
M. Masuda
Author of
-
+
P3.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 211)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.02-007 - Survival and Prognostic Factor in Pathological N1 Non-Small-Cell Lung Cancer (ID 2750)
09:30 - 09:30 | Author(s): M. Masuda
- Abstract
Background:
The 5-year survival rates of N1 non-small-cell lung cancer (NSCLC) were reported to be between 27% and 67%. The aim of the study was to identify common prognostic factors in NSCLC with N1 nodal involvement.
Methods:
The medical records and the follow-up data of the patients operated for NSCLC(p-N1) between January 1991 and December 2013 in Yokohama Rosai Hospital were analyzed retrospectively. Fifty-four patients with NSCLC (p-N1) who underwent lung resections with negative surgical margins were included in this study.
Results:
The subjects were 45 men and 9 women with a mean age of 67 years (range, 45-81 years). Among them 24 had adenocarcinoma, 16 had squamous cell carcinoma, 6 had large cell carcinoma, and 8 had the other histologies. T-factor of the primary tumor was T1 in 12 patients, T2 in 34, T3 in 7, and T4 in 1. Among N1 disease, peripheral zone lymph node (#12,13,14) metastasis was 18 cases, while hilar zone node(#10,11) metastasis was 30 cases, and both zone in 6 cases. The overall 5-year survival rates were 54.7 % in N1 disease. In a univariate analysis, survival was worse in case of higher T factor (T3,4) (p<0.01), multiple-N1-node involvement(p<0.01), and multiple-N1-zone involvement(p<0.01). Among patients with single-N1-zone involvement, overall survival was lower in patients with hilar zone metastasis than in those with peripheral zone metastasis, although this difference was not statistically significant (p=0.272).Figure 1
Conclusion:
In pN1 NSCLC patients, higher T-factor, multiple-N1-node involvement, and multiple-N1-zone involvement were worse prognostic factors.
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-048 - Rare Gene Mutations in Japanese Surgically Resected Non-Small-Cell Lung Cancer Patients (ID 2715)
09:30 - 09:30 | Author(s): M. Masuda
- Abstract
Background:
Driver gene mutations except for EGFR are rare in Japanese population. In this study, we investigated EGFR, KRAS, BRAF and PIK-3 mutations in surgically resected non-small-cell lung cancer (NSCLC).
Methods:
A total of 388 consecutive patients with NSCLC who underwent complete tumor resection in our hospital from 2006 through 2008 were studied retrospectively. Formalin-fixed, paraffin-embedded tissue sections were used to isolate DNA from carcinoma lesions. Mutational analyses of EGFR, KRAS, BRAF and PIK-3 were performed by loop-hybrid mobility shift assay, a highly sensitive polymerase chain reaction-based method.
Results:
We identified 185 EGFR mutations (47.7%), 33 KRAS mutations (8.5%), 3 BRAF mutations (0.77%), and 4 PIK-3 mutations (1.03%). In patients with BRAF mutation, all three patients were adenocarcinomas and smokers. There was no mutual mutation with EGFR and KRAS. PIK-3 mutations include 2 adenocarcinomas and 2 squamous cell carcinomas. Three of 4 patients were smoker. We found one PIK-3 and EGFR double mutation case.
Conclusion:
In Japanese surgically resected NSCLC, there are a lot of EGFR mutations, but there was little KRAS mutation. Although new molecular targeted therapy is expected, BRAF and PIK-3 mutations were very rare. Highly smoking rate in patients with KRAS and BRAF mutations was not different from past reports, but we could not find other clinical characteristics. Histopathologically, correlation between PIK-3 mutation and small cell carcinoma is attracting attention recently. In this study, histological types of cases with PIK-3 mutation were various.
